We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PacBio's (PACB) Latest Offering to Enhance Genome Analysis
Read MoreHide Full Article
Pacific Biosciences of California (PACB - Free Report) introduced a new informatics tool, Paraphase, to provide researchers with a highly accurate method of genotyping gene paralogs and pseudogenes.
This computational tool enables variant calling, copy number analysis and phasing. It does so by identifying the full sequence of each of the haplotypes for all genes and pseudogenes of the same gene family. Paraphase has been used on various medically relevant genes, including those related to spinal muscular atrophy, congenital adrenal hyperplasia, Ehlers-Danlos syndrome, and hereditary hearing loss and deafness.
With the help of this tool, researchers can better understand the underlying genetics of these complex genomic regions. They can also identify the silent carriers of disease-causing mutations.
Paraphase is being extended into a genome-wide generalized paralog caller and can act as a powerful tool for researchers to gain insight into medically relevant diseases.
Industry Prospects
Per a report by Data Bridge, the global genome sequencing market is projected to reach $55.7 billion in 2030 from $16.7 billion in 2022, at a CAGR of 16.2%. Factors like increasing cancer occurrence and the growing applications of next-generation sequencing in cancer research are expected to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen PacBio’s global business.
Earlier this month, PacBio started commercial shipment of Revio long-read sequencing system. It is designed to deliver higher throughput on a lower cost, offering exceptional accuracy and direct methylation detection.
The company expects to ship at least 25 Revio systems and plans to scale up going forward. It had received orders of 76 systems during the fourth quarter of 2022. Last month, the company announced robust increase in its Consumables revenues during the same quarter. However, service and other revenues, as well as product sales declined year over year.
In October 2022, PacBio announced the creation of Consortium for Long Read Sequencing, which aims to accelerate the utility of long-read human genome datasets. The same month, it also announced the availability of an initial portfolio of off-the-shelf long-read gene panels in collaboration with Twist Bioscience Corporation. One panel included coverage of nearly 400 challenging medically relevant genes, while the other was designed to capture 50 pharmacogenomic genes.
Zacks Rank & Stocks to Consider
PacBio currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the medical space are Becton, Dickinson and Company (BDX - Free Report) , Henry Schein (HSIC - Free Report) and The Cooper Companies (COO - Free Report) .
Becton, Dickinson and Company, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth of 7.8%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.47%.
BDX’s shares have declined 9.9% against the industry’s 0.7% growth in the past six months.
Henry Schein, carrying a Zacks Rank #2 at present, has an estimated long-term growth of 8.1%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, the average surprise being 2.97%.
HSIC’s shares have gained 7.8% compared with the industry’s 0.8% growth in the past six months.
The Cooper Companies, carrying a Zacks Rank #2 at present, has an estimated long-term growth of 11%. Its earnings missed estimates in three of the trailing four quarters and beat the same once, the average negative surprise being 1.82%.
COO’s shares have gained 11.3% compared with the industry’s 0.8% growth over the past six months.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
PacBio's (PACB) Latest Offering to Enhance Genome Analysis
Pacific Biosciences of California (PACB - Free Report) introduced a new informatics tool, Paraphase, to provide researchers with a highly accurate method of genotyping gene paralogs and pseudogenes.
This computational tool enables variant calling, copy number analysis and phasing. It does so by identifying the full sequence of each of the haplotypes for all genes and pseudogenes of the same gene family. Paraphase has been used on various medically relevant genes, including those related to spinal muscular atrophy, congenital adrenal hyperplasia, Ehlers-Danlos syndrome, and hereditary hearing loss and deafness.
With the help of this tool, researchers can better understand the underlying genetics of these complex genomic regions. They can also identify the silent carriers of disease-causing mutations.
Paraphase is being extended into a genome-wide generalized paralog caller and can act as a powerful tool for researchers to gain insight into medically relevant diseases.
Industry Prospects
Per a report by Data Bridge, the global genome sequencing market is projected to reach $55.7 billion in 2030 from $16.7 billion in 2022, at a CAGR of 16.2%. Factors like increasing cancer occurrence and the growing applications of next-generation sequencing in cancer research are expected to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen PacBio’s global business.
Pacific Biosciences of California, Inc. Price
Pacific Biosciences of California, Inc. price | Pacific Biosciences of California, Inc. Quote
Recent Developments
Earlier this month, PacBio started commercial shipment of Revio long-read sequencing system. It is designed to deliver higher throughput on a lower cost, offering exceptional accuracy and direct methylation detection.
The company expects to ship at least 25 Revio systems and plans to scale up going forward. It had received orders of 76 systems during the fourth quarter of 2022. Last month, the company announced robust increase in its Consumables revenues during the same quarter. However, service and other revenues, as well as product sales declined year over year.
In October 2022, PacBio announced the creation of Consortium for Long Read Sequencing, which aims to accelerate the utility of long-read human genome datasets. The same month, it also announced the availability of an initial portfolio of off-the-shelf long-read gene panels in collaboration with Twist Bioscience Corporation. One panel included coverage of nearly 400 challenging medically relevant genes, while the other was designed to capture 50 pharmacogenomic genes.
Zacks Rank & Stocks to Consider
PacBio currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the medical space are Becton, Dickinson and Company (BDX - Free Report) , Henry Schein (HSIC - Free Report) and The Cooper Companies (COO - Free Report) .
Becton, Dickinson and Company, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth of 7.8%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.47%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BDX’s shares have declined 9.9% against the industry’s 0.7% growth in the past six months.
Henry Schein, carrying a Zacks Rank #2 at present, has an estimated long-term growth of 8.1%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, the average surprise being 2.97%.
HSIC’s shares have gained 7.8% compared with the industry’s 0.8% growth in the past six months.
The Cooper Companies, carrying a Zacks Rank #2 at present, has an estimated long-term growth of 11%. Its earnings missed estimates in three of the trailing four quarters and beat the same once, the average negative surprise being 1.82%.
COO’s shares have gained 11.3% compared with the industry’s 0.8% growth over the past six months.